Neeland, Ian J.
Singh, Shruti
McGuire, Darren K.
Vega, Gloria L.
Roddy, Thomas
Reilly, Dermot F.
Castro-Perez, Jose
Kozlitina, Julia
Scherer, Philipp E.
Funding for this research was provided by:
National Center for Advancing Translational Sciences (UL1TR001105)
Merck (Investigator Initiated Study)
National Institute of Diabetes and Digestive and Kidney Diseases (K23 DK106520)
Donald W. Reynolds Foundation (Dallas Heart Study)
Article History
Received: 15 May 2018
Accepted: 20 July 2018
First Online: 29 August 2018
Duality of interest
: IJN has received honoraria, consulting and speaking fees and travel support from Boehringer Ingelheim/Lilly Alliance (significant), a research grant from Novo Nordisk (significant) and is a member of the scientific advisory board of Advanced MR Analytics (modest). DKM reports clinical trial leadership for AstraZeneca (modest), Sanofi Aventis (modest), Janssen (modest), Boehringer Ingelheim (significant), Merck & Co (modest), Novo Nordisk (significant), Lexicon (modest), Eisai (modest), GlaxoSmithKline (modest), Esperion (modest); consultancy for AstraZeneca (modest), Sanofi Aventis (significant), Lilly US (modest), Boehringer Ingelheim (significant), Merck & Co, Pfizer (modest), Novo Nordisk (significant), Metavant (modest). TR, DFR and JC-P are employees of Merck & Co. or were employees when the ceramide measurements were performed.
Free to read: This content has been made available to all.